Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts.
We’re all quite familiar with the lateral flow test now, since the COVID-19 pandemic where they were used to test for infection with the virus, but now developers from Aptamer Group working with the biotechnology group Neuro-Bio, have devised a lateral flow test for Alzheimer’s disease.
Apatamer Group are behind the novel Optimer® binders, to be used in the life sciences industry. Neuro-Bio used their expertise to develop therapies for neurodegenerative diseases. Coming together, they have developed a panel of Optimer binders to a novel Alzheimer’s disease biomarker. The binders have demonstrated good performance in binding to the target biomarker in a nasal mucous matrix, once incorporated into a lateral flow testing kit the test will be able to be used for rapid detection of Alzheimer’s in a nasal sample.
The test could be used for clinical diagnostics for the disease in the early stages, even as much as 10–20 years before the onset of symptoms. The novel biomarker is a peptide – T14 – discovered and currently being validated further by a team led by Susan Greenfield at Neuro-Bio.
Being able to detect Alzheimer’s disease early on is paramount to starting treatments and preventative therapies to mitigate the effects of the disease in patients, including memory loss and confusion. Neuro-Bio is also working on a therapy to compliment the diagnostic breakthrough, with a view to halting disease progression in patients diagnosed with Alzheimer’s disease at this early stage before symptoms occur.
Rob Quinn, Interim Chief Executive Officer of Aptamer Group, commented:
“We are pleased to be able to support the team at Neuro-Bio with the development of Optimer binders to enable their revolutionary diagnostic for Alzheimer’s disease. Optimer binders have proven performance in lateral flow test formats and our success in delivering functional Optimer binders to Neuro-Bio’s biomarker facilitates further diagnostic development. With an increasingly aging population and no current tests available for early-stage diagnosis, the advancement of new biomarkers and diagnostics in this field offers hope to the millions of patients and their loved ones worldwide.”
Susan Greenfield, CEO of Neuro-Bio, added:
“We’re delighted to be working with Aptamer Group on this potentially game-changing technology to combat one of the biggest unmet medical needs of our time. It’s a further example of UK ingenuity and teamwork for highly innovative and disruptive science.”
Source: Aptamer Group. Aptamer Group and Neuro-Bio partner to develop an Alzheimer’s disease diagnostic test. [Date accessed 15.06.2023]
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers?
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance